When considering the clinical utility of screening for a new marker of cardiovascular disease, physicians should determine
whether a standardized and reproducible assay for the marker is available, whether a consistent series of prospective studies
indicate that baseline elevations of the marker predict future risk, and whether assessment of the marker adds to the predictive
value of other plasma-based risk factors.